The Phase III trial of NovaRx Corp.‘s Lucanix (belagenpumatucel-L) missed the primary endpoint of improving overall survival in 532 patients with non-small cell lung cancer (NSCLC). There were positive results in a prominent. In the predefined subgroup of 305 stage IIIb/IV patients enrolled within 12 weeks of the completion of frontline chemotherapy, a median survival of 20.7 months was observed for Lucanix compared to 13.4 months for the control. In a predefined subgroup of these patient...